A study of 790 men by the U.S. National Cancer Institute found that prostate cancer sufferers who receive hormonal therapy along with the chemotherapy drug docetaxel for 18 weeks lived longer, on average, than those who received hormonal therapy only. The study split the men into two groups, the group that receive the docetaxel had a median survival of 57.6 months, compared to just 44 months for the hormonal therapy-only group, CBS News notes.

Scientists also found that adding the chemotherapy drug delayed the spread of the progression of prostate cancer as well. Men who received the chemotherapy drug had a median time to progression after treatment of 32.7 months, compared to just 19.8 months for those who received only hormonal therapy.

Results of the study were presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago over the weekend.